Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Past Issues
    • Accepted Articles
    • Email Alerts
    • RSS
    • Terms of Use
  • About PDA JPST
    • JPST Editors and Editorial Board
    • About/Vision/Mission
    • Paper of the Year
  • Author & Reviewer Resources
    • Author Resources / Submit
    • Reviewer Resources
  • JPST Access and Subscriptions
    • PDA Members
    • Institutional Subscriptions
    • Nonmember Access
  • Support
    • Join PDA
    • Contact
    • Feedback
    • Advertising
    • CiteTrack
  • .
    • Visit PDA
    • PDA Letter
    • Technical Reports
    • news uPDATe
    • Bookstore

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
PDA Journal of Pharmaceutical Science and Technology
  • .
    • Visit PDA
    • PDA Letter
    • Technical Reports
    • news uPDATe
    • Bookstore
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
PDA Journal of Pharmaceutical Science and Technology

Advanced Search

  • Home
  • Content
    • Current Issue
    • Past Issues
    • Accepted Articles
    • Email Alerts
    • RSS
    • Terms of Use
  • About PDA JPST
    • JPST Editors and Editorial Board
    • About/Vision/Mission
    • Paper of the Year
  • Author & Reviewer Resources
    • Author Resources / Submit
    • Reviewer Resources
  • JPST Access and Subscriptions
    • PDA Members
    • Institutional Subscriptions
    • Nonmember Access
  • Support
    • Join PDA
    • Contact
    • Feedback
    • Advertising
    • CiteTrack
  • Follow pda on Twitter
  • Visit PDA on LinkedIn
  • Visit pda on Facebook
Research ArticleConference Proceeding

Regulatory Considerations for Raw Materials Used in Biological Products

A. S. Khan
PDA Journal of Pharmaceutical Science and Technology September 2010, 64 (5) 451-457;
A. S. Khan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Arifa.Khan@fda.hhs.gov
  • Article
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
Loading

References

  1. 1.↵
    1. Anderson K. P.,
    2. Low M. A.,
    3. Lie Y. S.,
    4. Keller G. A.,
    5. Dinowitz M.
    Endogenous origin of defective retrovirus-like particles from a recombinant Chinese hamster ovary cell line. Virology 1991, 181 (1), 305–311.
    OpenUrlPubMed
  2. 2.↵
    1. Khan A. S.,
    2. Maudru T.,
    3. Thompson A.,
    4. Muller J.,
    5. Sears J. F.,
    6. Peden K. W.
    The reverse transcriptase activity in cell-free medium of chicken embryo fibroblast cultures is not associated with a replication-competent retrovirus. J. Clin. Virol. 1998, 11 (1): 7–18.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Robertson J. S.,
    2. Nicolson C.,
    3. Riley A. M.,
    4. Bentley M.,
    5. Dunn G.,
    6. Corcoran T.,
    7. Schild G. C.,
    8. Minor P.
    Assessing the significance of reverse transcriptase activity in chick cell-derived vaccines. Biologicals 1997, 25 (4), 401–414.
    OpenUrl
  4. 4.↵
    1. Tsang S. X.,
    2. Switzer W. M.,
    3. Shanmugam V.,
    4. Johnson J. A.,
    5. Goldsmith C.,
    6. Wright A.,
    7. Fadly A.,
    8. Thea D.,
    9. Jaffe H.,
    10. Folks T. M.,
    11. Heneine W.
    Evidence of avian leukosis virus subgroup E and endogenous avian virus in measles and mumps derived from chicken cells: investigation of transmission to vaccine recipients. J. Virol. 1999, 73 (7), 5843–5851.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Weissmahr R. N.,
    2. Schupbach J.,
    3. Boni J.
    Reverse transcriptase activity in chicken supernatants is associated with particles containing endogenous avian retrovirus EAV-0 RNA. J. Virol. 1997, 71 (4), 3005–3012.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Waters T. D.,
    2. Anderson P. S. Jr..,
    3. Beebe G. W.,
    4. Miller R. W.
    Yellow fever vaccination, avian leukosis virus, and cancer risk in man. Science 1972, 177 (43), 76–77.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Melnick J. L.,
    2. Stinebaugh S.
    Excretion of vaculoating SV-40 virus (papova virus group) after ingestion as a contaminant of oral poliovaccine. Proc. Soc. Exp. Biol. Med. 1962, 109, 965–968.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Sweet B. H.,
    2. Hilleman M. R.
    The vacuolating virus SV 40. Proc. Soc. Exp. Biol. Med. 1960, 105, 420–427.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Li T.-C.,
    2. Scotti P. D.,
    3. Miyamura T.,
    4. Tadeka N.
    Latent infection of a new alphanodavirus in an insect cell line. J. Virol. 2007, 81 (20), 10890–10896.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Gurtler L.
    Blood-borne viral infections. Blood Coagul. Fibrinolysis 1994, 5 (Suppl. 3), S5–S12.
    OpenUrl
  11. 11.↵
    1. Horowitz B.
    Specific Inactivation of Viruses Which Can Potentially Contaminate Blood Products. In Virological Aspects of the Safety of Biological Products; Karger: Basel, 1991; Vol. 75, pp 43–52.
    OpenUrl
  12. 12.↵
    1. Horaud F.,
    2. Brown F.
    1. Vicari G.
    Validation of Purification Procedures for Removing and/or Inactivating Viruses in Biologicals: Points To Consider. In Virological Aspects of the Safety of Biological Products; Horaud F., Brown F., Eds.; Karger: Basel, 1991; Vol. 75, pp 227–232.
    OpenUrl
  13. 13.↵
    1. Hollak C. E. M.,
    2. vom Dahi S.,
    3. Aerts J. M.,
    4. Belmatoug N.,
    5. Bembi B.,
    6. Cohen Y.,
    7. Collin-Histed T.,
    8. Deegan P.,
    9. van Dussen L.,
    10. Giraldo P.,
    11. Mengel E.,
    12. Michelakakis H.,
    13. Manuel J.,
    14. Hrebicek M.,
    15. Parini R.,
    16. Reinke J.,
    17. di Rocco M.,
    18. Pocovi M.,
    19. Sa Miranda MC.,
    20. Tylki-Szymanska A.,
    21. Zimran A.,
    22. Cox TM.
    Force majeure: therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher disease. Blood Cells Mol. Dis. 2010, 44 (1), 41–47.
    OpenUrlCrossRefPubMedWeb of Science
  14. 14.↵
    http://www.fda.gov/cber/advisoryvrbp/vrbpmain.htm.
  15. 15.↵
    1. Victoria J. G.,
    2. Wang C.,
    3. Jones M. S.,
    4. Jaing C.,
    5. McLoughlin K.,
    6. Gardner S.,
    7. Delwart E. L.
    Viral nucleic acids in live-attenuated vaccines: detection of minority variants and an adventitious virus. J. Virol. 2010, 84 (12), 6033–6040.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    Code of Federal Regulations, Title 9, Animal and Animal Products (current year): Part 113.53, Requirements for ingredients of animal origin used for production of biologics. Office of the Federal Register, National Archives and Records Administration, U.S. Government Printing Office: Washington DC. January 1, 2010.
  17. 17.↵
    1. Chen D.,
    2. Nims R.,
    3. Dusing S.,
    4. Miller P.,
    5. Luo W.,
    6. Quertinmont M.,
    7. Parekh B.,
    8. Poorbaugh J.,
    9. Boose J. A.,
    10. Atkinson E. M.
    Root cause investigation of a viral contamination incident occurred during master cell bank (MCB) testing and characterization—a case study. Biologicals 2008, 36 (6), 393–402.
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Brown F.,
    2. Lewis A. M.,
    3. Peden K.,
    4. Krause P.
    1. Hayflick L.
    A Brief History of Cell Substrates Used for the Preparation of Human Biologicals. In Evolving Scientific and Regulatory Perspectives on Cell Substrates for Vaccine Development; Brown F., Lewis A. M., Peden K., Krause P., Eds.; Karger: Basel, 2001, Vol. 106, pp 5–24.
    OpenUrlPubMed
  19. 19.↵
    http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM093833.htm.
  20. 20.↵
    1. Khan A. S.
    Characterization and qualification of cell substrates for manufacturing viral vaccines in the United States. BioProcessing Journal 2009, 8, 8–12.
    OpenUrl
  21. 21.↵
    1. Horaud F.,
    2. Brown F.
    1. Erickson G. A.,
    2. Bolin S. R.,
    3. Landgraf J. G.
    Viral Contamination of Fetal Bovine Serum Used for Tissue Culture: Risks and Concerns. In Virological Aspects of the Safety of Biological Products; Horaud F., Brown F., Eds.: Karger: Basel, 1991; Vol. 75, pp 173–175.
    OpenUrl
  22. 22.↵
    1. Brown F.,
    2. Lewis A. M.,
    3. Peden K.,
    4. Krause P.
    1. Griffiths E.
    Major Issues Associated with the Use of Cell Substrates for the Production of Vaccines. In Evolving Scientific and Regulatory Perspectives on Cell Substrates for Vaccine Development; Brown F., Lewis A. M., Peden K., Krause P., Eds.; Karger: Basel, 2001; Vol. 106, pp 25–36.
    OpenUrlPubMed
  23. 23.↵
    1. Horaud F.,
    2. Brown F.
    1. Hay R. J.
    Operator-Induced Contamination in Cell Culture Systems. In Virological Aspects of the Safety of Biological Products; Horaud F., Brown F., Eds.; Karger: Basel, 1991; Vol. 75, pp 193–204.
    OpenUrl
  24. 24.↵
    1. Merten O. W.
    Virus contaminations of cell cultures—A biotechnological view. Cytotechnology 2002, 39 (2), 91–116.
    OpenUrlCrossRefPubMedWeb of Science
  25. 25.↵
    1. Petricciani J. C.
    An overview of viral and viral-like agents in cell culture systems. Cytotechnology 1998, 28 (1–3), 49–52.
    OpenUrlPubMed
  26. 26.↵
    1. Pastoret P. P.
    Human and animal vaccine contaminations. Biologicals 2010, 38 (3), 332–334.
    OpenUrlPubMed
  27. 27.↵
    Center for Biologics Evaluation and Research (CBER). Points to consider in the characterization of cell lines used to produce biologicals. U.S. Food and Drug Administration (FDA): Rockville, MD, July 1993.
  28. 28.↵
    CBER. Points to consider in the manufacture and testing of monoclonal antibody products for human use. U.S. FDA: Rockville, MD, February 1997.
  29. 29.↵
    CBER. Guidance for industry: Characterization and qualification of cell substrates and other biological materials used in the production of viral vaccines for infectious disease indications. U.S. FDA: Rockville, MD, February 2010.
  30. 30.↵
    CBER. Guidance for industry: Supplemental guidance on testing for replication competent retrovirus in retroviral vector based gene therapy products and during follow-up of patients in clinical trials using retroviral vectors. U.S. FDA: Rockville, MD, November 2006.
  31. 31.↵
    CBER. Guidance for Industry: Source Animal, Product, Preclinical, and Clinical Issues Concerning the Use of Xenotransplantation Products in Humans. April 2003.
  32. 32.↵
    Code of Federal Regulations, Title 21, Part 610. Food and Drugs, General Biological Products Standards. Office of the Federal Register, National Archives and Records Administration, U.S. Government Printing Office: Washington, DC. April 1, 2009.
  33. 33.↵
    International Conference on Harmonization. ICH Topics Q5D—Guidance on derivation and characterization of cell substrates used for production of biotechnological/biological products. 21 Sept 1998.
  34. 34.↵
    International Conference on Harmonisation. ICH Topics Q5A(R1)—Viral safety evaluation of biotechnology products derived from cell lines of human or animal origin. 23 Sept 1999.
  35. 35.↵
    World Health Organization (WHO). WHO Expert Committee on Biological Standardization, 47th Report: Requirements for the use of animal cells as in vitro substrates for the production of biologicals. WHO Technical Report Series, No. 878, annex 1., 1998.
  36. 36.↵
    1. Ulrey A. K.,
    2. Curren R. D.,
    3. Raabe H. A.
    The importance of supplier qualification for vendors of materials used in in vitro assays. AATEX 14 2008, (Special Issue), 595–600.
  37. 37.↵
    1. Wessman S. J.,
    2. Levings R. L.
    Collective experiences of adventitious viruses of animal-derived raw materials and what can be done about them. Cytotechnology 1998, 28 (1–3), 43–48.
    OpenUrlPubMed
  38. 38.↵
    1. Harasawa R. M.,
    2. Sasaki T.
    Sequence analysis of the 5′ untranslated region of pestivirus RNA demonstrated in interferons for human use. Biologicals 1995, 23 (4), 263–269.
    OpenUrlCrossRefPubMed
  39. 39.↵
    1. Harasawa R.,
    2. Tomiyama T.
    Evidence of pestivirus RNA in human virus vaccines. J. Clin. Microbiol. 1994, 32 (6), 1604–1605.
    OpenUrlAbstract/FREE Full Text
  40. 40.↵
    1. Nims R. W.
    Detection of adventitious viruses in biologicals—a rare occurrence. Dev. Biol. (Basel) 2006, 123, 153–164.
    OpenUrlPubMed
  41. 41.↵
    1. Burstyn D. G.
    Contamination of genetically engineered Chinese hamster ovary cells. Dev. Biol. Stand. 1996, 88, 199–203.
    OpenUrlPubMed
  42. 42.↵
    1. Rabenau H.,
    2. Ohlinger V.,
    3. Anderson J.,
    4. Selb B.,
    5. Cinatl J.,
    6. Wolf W.,
    7. Frost J.,
    8. Mellor P.,
    9. Doerr H. W.
    Contamination of genetically engineered CHO-cells by epizootic haemorrhagic disease virus (EHDV). Biologicals 1993, 21 (3), 207–214.
    OpenUrlCrossRefPubMed
  43. 43.↵
    1. Nettleton P. F.,
    2. Rweyemanu M. M.
    The association of calf serum with the contamination of BHK21 clone 13 suspension cells by a parvovirus serologically related to the minute virus of mice (MVM). Arch. Virol. 1980, 64 (4), 359–374.
    OpenUrlPubMed
  44. 44.↵
    1. Garnick R. L.
    Experience with viral contamination in cell culture. Dev. Biol. Stand. 1996, 88, 49–56.
    OpenUrlPubMed
  45. 45.↵
    1. Fiebig E. W.,
    2. Busch M. P.
    Emerging infections in transfusion medicine. Clin. Lab. Med. 2004, 24 (3), 797–823.
    OpenUrlPubMed
PreviousNext
Back to top

In This Issue

PDA Journal of Pharmaceutical Science and Technology: 64 (5)
PDA Journal of Pharmaceutical Science and Technology
Vol. 64, Issue 5
September/October 2010
  • Table of Contents
  • Index by Author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on PDA Journal of Pharmaceutical Science and Technology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Regulatory Considerations for Raw Materials Used in Biological Products
(Your Name) has sent you a message from PDA Journal of Pharmaceutical Science and Technology
(Your Name) thought you would like to see the PDA Journal of Pharmaceutical Science and Technology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
13 + 1 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Regulatory Considerations for Raw Materials Used in Biological Products
A. S. Khan
PDA Journal of Pharmaceutical Science and Technology Sep 2010, 64 (5) 451-457;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Regulatory Considerations for Raw Materials Used in Biological Products
A. S. Khan
PDA Journal of Pharmaceutical Science and Technology Sep 2010, 64 (5) 451-457;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • History of Virus Contaminations Due to Raw Materials
    • Safety Issues Related to Biological Raw Materials
    • Considerations for Developing a Comprehensive Testing Scheme for Product Safety
    • Qualification and Management of Raw Materials
    • Efforts toward Designing Safety in Biologics
    • Acknowledgments
    • References
  • Figures & Data
  • References
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • A Multicenter Study To Evaluate the Performance of High-Throughput Sequencing for Virus Detection
  • Current Testing Methods and Challenges for Detection of Adventitious Viruses
  • Mouse Minute Virus (MMV) Contamination--A Case Study: Detection, Root Cause Determination, and Corrective Actions
  • Detection of Latent Retroviruses in Vaccine-related Cell Substrates: Investigation of RT Activity Produced by Chemical Induction of Vero Cells
  • Google Scholar

More in this TOC Section

Conference Proceeding

  • Proceedings of the 2017 Viral Clearance Symposium, Session 2.2: DSP Unit Operations–Purification Unit Operations
  • Proceedings of the 2017 Viral Clearance Symposium—
  • Proceedings of the 2017 Viral Clearance Symposium, Session 4: Submission Strategies
Show more Conference Proceeding

Raw Materials

  • Raw Materials Case Histories
  • TSE Case Studies Associated with Japanese and Other Regulatory Authorities—Talk Transcript
  • Raw Materials in the Manufacture of Biotechnology Products: Regulatory Considerations
Show more Raw Materials

Similar Articles

Readers

  • About
  • Table of Content Alerts/Other Alerts
  • Subscriptions
  • Terms of Use
  • Contact Editors

Author/Reviewer Information

  • Author Resources
  • Submit Manuscript
  • Reviewers
  • Contact Editors

Parenteral Drug Association, Inc.

  • About
  • Advertising/Sponsorships
  • Events
  • PDA Bookstore
  • Press Releases

© 2025 PDA Journal of Pharmaceutical Science and Technology Print ISSN: 1079-7440  Digital ISSN: 1948-2124

Powered by HighWire